Core Viewpoint - The company, Shiyao Group, has received FDA approval for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) to conduct clinical trials in the United States, with additional approval from China's National Medical Products Administration for trials starting in November 2025 [1] Group 1: Product Details - JMT206 specifically binds to both ActRIIA and ActRIIB receptors, blocking the interaction of activin A, myostatin, and growth differentiation factor 11 with ActRII, thereby inhibiting downstream signaling pathways [1] - The product aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in individuals who are obese or overweight and have at least one weight-related comorbidity [1] - The product is also designed to assist GLP-1 receptor agonists in achieving higher quality weight loss outcomes [1]
石药集团JMT206在美国获临床试验批准